Tag: trial

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Olo Inc. (NYSE: OLO) related to its sale to Thoma Bravo for $10.25 per share in cash to Olo shareholders. Is it a fair deal?

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating WNS (Holdings) Limited (NYSE: WNS) related to its sale to Capgemini, S.E. for $76.50 per share in cash to WNS shareholders. Is it a fair deal?

PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’),  a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced two important developments that aim to reinforce the global positioning of potential first-in-class radioenhancer JNJ-1900 (NBTXR3), which is licensed by Janssen Pharmaceutica NV, a Johnson & Johnson company.

Half-year statement of IPSEN liquidity agreement with NATIXIS ODDO BHF

Planned submission of IND application in 2025; Phase 1 clinical trial to follow if IND application approved

Highland, Indiana, July 07, 2025 (GLOBE NEWSWIRE) -- REsimpli, a leading all-in-one AI CRM for Real Estate Investors, is thrilled to announce the launch of its REsimpli 5.0 release that introduces 8 powerful AI Agent tools and a List Pulling Feature that help investors pull off-market properties with necessary filters for the best results. These tools are designed to automate communication, reduce response times, and dramatically improve conversion rates.

-- Patients treated with bezuclastinib showed a superior mean change in total symptom score at 24 weeks (-24.3 points vs. -15.4 points, -8.91 point placebo-adjusted difference; p=0.0002), compared to patients treated with placebo, establishing new benchmarks for placebo-adjusted and absolute symptomatic improvement for this patient population --

-- Bezuclastinib demonstrated a powerful effect on mast cell burden, with 87.4% of patients treated with bezuclastinib achieving at least 50% reduction in serum tryptase compared to 0% of patients treated with placebo --

PARIS, July 07, 2025 (GLOBE NEWSWIRE) --  PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, is pleased to announce that the first patient has been successfully dosed in its Phase I clinical trial (PST-611-CT1) aiming to assess safety and tolerability of its lead program, PST-611, in humans.